newsCould novel antibiotic successfully treat a ‘priority 1 pathogen’?19 January 2024 | By Catherine Eckford (European Pharmaceutical Review)Highlighting the potential of a novel antibiotic against acinetobacter infections, GlobalData explained that nine other drugs, alongside this promising treatment, are in clinical development for this indication.
newsAntibiotics ‘no longer effective’ for childhood infections, finds study2 November 2023 | By Caroline Peachey (European Pharmaceutical Review)Australian-led study highlights ‘alarmingly high’ rates of resistance to commonly-prescribed antibiotics in the Asia-Pacific region.
newsWHO prequalifies meningitis conjugate vaccine12 July 2023 | By Catherine Eckford (European Pharmaceutical Review)Prequalification by the World Health Organization (WHO) for the first conjugate vaccine to prevent meningitis caused by meningococcal group X could help “finally end all meningococcal meningitis epidemics in Africa”.
newsGSK to acquire Affinivax for MAPS vaccine platform31 May 2022 | By Hannah Balfour (European Pharmaceutical Review)GSK will pay up to $3.3 billion to acquire Affinivax, gaining access to its Multiple Antigen Presenting System (MAPS) technology and pneumococcal vaccine candidates.
newsPromising results for COVID-19 and pneumococcal vaccine co-administration14 January 2022 | By Hannah Balfour (European Pharmaceutical Review)Pfizer reveals co-administering its Prevnar 20™ pneumococcal vaccine and a booster dose of Comirnaty® COVID-19 vaccine was safe and immunogenic.
newsEC approves new meningitis vaccine25 November 2020 | By Hannah Balfour (European Pharmaceutical Review)MenQuadfi® has been approved for use in individuals 12 months of age and older, based on its safety and immunogenicity in 6,300 trial subjects.
newsFirst patients dosed in GSK’s Phase III meningitis vaccine trial27 August 2020 | By Hannah Balfour (European Pharmaceutical Review)The trial will assess the safety, tolerability and immunogenicity of the five-in-one MenABCWY vaccine in participants aged 10 to 25.
newsEMA begins safety review of ifosfamide cancer medicines16 March 2020 | By Victoria Rees (European Pharmaceutical Review)The EMA has announced the results of its pharmacovigilance meeting for March, saying that it has started a review of medicines containing ifosfamide due to a higher risk of encephalopathy.
newsMenABCWY set to revolutionise the meningococcal vaccine market29 June 2016 | By Victoria White, Digital Content ProducerGlobalData says MenABCWY has the potential to significantly change the approach used to prevent meningococcal disease...
newsMeningococcal vaccines market to approach $1.8b by 2025, says GlobalData7 June 2016 | By Victoria White, Digital Content ProducerThe meningococcal vaccines market is expected to grow from around $1.1 billion in 2015 to $1.8 billion by 2025, according to GlobalData...
newsStudies demonstrate immunogenicity of Trumenba against MnB13 May 2016 | By Victoria White, Digital Content ProducerPfizer has announced results of two Phase III studies demonstrating the immunogenicity of Trumenba against invasive meningococcal B strains...
newsMenB vaccine Bexsero might see private uptake in the UK9 March 2016 | By GlobalDataThe UK Department of Health’s rejection of a petition to expand the routine administration of MenB vaccine Bexsero may lead to parents and physicians to consider purchasing the vaccine themselves...
newsAfrica risks large meningitis C outbreak28 July 2015 | By Victoria WhiteFour public health organisations have warned of acute shortages of meningitis C-containing vaccine as the risk of a meningitis C outbreak in Africa grows...
newsPfizer to acquire GSK meningitis vaccines22 June 2015 | By Victoria WhitePfizer has entered into an agreement with GlaxoSmithKline to acquire its quadrivalent meningitis ACWY vaccines, Nimenrix and Mencevax, for $130 million...
